Stockreport

Unum Therapeutics Implements Strategic Restructuring to Prioritize Efforts on BOXR1030 for the Treatment of Solid Tumor Cancers

UNUM THERAPEUTICS INC COMMON  (UMRX) 
Last unum therapeutics inc common earnings: 3/26 07:30 am Check Earnings Report
PDF BOXR1030 is a GPC3-targeted CAR T cell incorporating the novel GOT2 transgene designed to improve T cell function in the solid tumor microenvironment by enhancing T cell [Read more]